Prevalence of Autism Spectrum Disorder in 7–9-Year-Old Children in Denmark, Finland, France and Iceland: A Population-Based Registries Approach Within the ASDEU Project

2019 ◽  
Vol 50 (3) ◽  
pp. 949-959 ◽  
Author(s):  
M. Delobel-Ayoub ◽  
E. Saemundsen ◽  
M. Gissler ◽  
A. Ego ◽  
I. Moilanen ◽  
...  
Author(s):  
Paul T. Shattuck ◽  
Maureen Durkin ◽  
Matthew Maenner ◽  
Craig Newschaffer ◽  
David S. Mandell ◽  
...  

2019 ◽  
Vol 50 (2) ◽  
pp. 625-633 ◽  
Author(s):  
Basmah H. Alfageh ◽  
Kenneth K. C. Man ◽  
Frank M. C. Besag ◽  
Tariq M. Alhawassi ◽  
Ian C. K. Wong ◽  
...  

Abstract Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing.


2019 ◽  
Vol 61 (2) ◽  
pp. 131-139 ◽  
Author(s):  
Gillian M. Maher ◽  
Gerard W. O'Keeffe ◽  
Christina Dalman ◽  
Patricia M. Kearney ◽  
Fergus P. McCarthy ◽  
...  

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Maria E. Verhoeff ◽  
Laura M. E. Blanken ◽  
Desana Kocevska ◽  
Viara R. Mileva-Seitz ◽  
Vincent W. V. Jaddoe ◽  
...  

Author(s):  
Deepa Singal ◽  
Dan Chateau ◽  
Matthew Dahl ◽  
Shelley Derksen ◽  
Chelsea Ruth ◽  
...  

IntroductionMany studies demonstrating an association between in utero exposure to serotonergic antidepressants and higher risk of neurodevelopmental disorders in children are confounded by history of maternal depression and disease severity. We conducted a population-based analysis of women diagnosed with mood/anxiety disorder, a patient population for whom pharmacotherapy is clearly indicated. Objectives and ApproachUsing linked population-based administrative data, we identified all mother-newborn pairs in Manitoba (born 1996 to 2009, with follow-up through 2014). High dimensional propensity scores and inverse probability treatment weighting were used to address confounding by indication and disease severity. The final trimmed cohort consisted of mothers who were diagnosed with a mood/anxiety disorder from 90 days prior to conception until delivery (n=4995). Cox Proportional Hazard Regression models were used to estimate risk of Autism Spectrum Disorder, epilepsy and attention deficit hyperactivity disorder (ADHD) in offspring. In addition to clinical data, we used novel education data to define outcomes in children. ResultsAmong the cohort of mothers diagnosed with a mood/anxiety disorder during pregnancy or up to 90 days before, 16.8% received at least two dispensations of an SSRI or SNRI during pregnancy. We did not observe an association between use of SSRIs/SNRIs during pregnancy and increased risk of Autism Spectrum Disorder (hazard ratio 0.92; 95% CI 0.42 to 2.03), epilepsy (hazard ratio 1.21; 95% CI 0.48 to 3.05), or ADHD (hazard ratio 1.13, 95% CI 0.78 to 1.64) among offspring. Conclusion/ImplicationsIn the absence of randomized control trials, large observation studies using sophisticated data analysis are the gold standard of evidence to help patients and clinicians making the decision to continue antidepressant use during pregnancy. Results of this study reassure women for whom the medication is clinically indicated.


Sign in / Sign up

Export Citation Format

Share Document